MARX Biotech Co., Ltd. (TPEX:7731)
Taiwan · Delayed Price · Currency is TWD 4.220
-0.040 (-0.94%)
Sep 9, 2026, 1:43 PM CST
MARX Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 584.74 | 635.85 | 618.23 | 289.93 | 110.64 | - | |
Revenue Growth | -17.97% | 2.85% | 113.24% | 162.04% | - | - |
Cost of Revenue | 287.75 | 241.26 | 188.16 | 75.33 | 26.43 | - |
Gross Profit | 296.99 | 394.59 | 430.07 | 214.59 | 84.21 | - |
Selling, General & Admin | 444.98 | 533.74 | 481.47 | 228.19 | 82.32 | 0.83 |
Research & Development | 0.32 | 0.32 | 25.99 | 0.74 | - | - |
Operating Expenses | 449.74 | 536.74 | 515.07 | 231.48 | 83.31 | 0.83 |
Operating Income | -152.74 | -142.15 | -85 | -16.89 | 0.9 | -0.83 |
Interest Expense | -11.07 | -13.69 | -2.21 | -0.37 | -0.11 | - |
Interest & Investment Income | 0.62 | 0.57 | 0.85 | 0.53 | 0.04 | - |
Earnings From Equity Investments | - | - | - | - | - | 4.97 |
Currency Exchange Gain (Loss) | -0.12 | 0.02 | 0.06 | - | - | - |
Other Non Operating Income (Expenses) | 0.93 | 2.12 | -11.68 | 1.24 | 4.09 | 0.15 |
EBT Excluding Unusual Items | -162.38 | -153.14 | -97.99 | -15.49 | 4.91 | 4.29 |
Gain (Loss) on Sale of Assets | 210.83 | 210.84 | - | - | - | - |
Other Unusual Items | 0.07 | 0.07 | 0.55 | - | - | - |
Pretax Income | 48.51 | 57.78 | -97.43 | -15.49 | 4.91 | 4.29 |
Income Tax Expense | 17.24 | 15.6 | -0.61 | -2.57 | 2.08 | -0.14 |
Earnings From Continuing Operations | 31.27 | 42.18 | -96.83 | -12.92 | 2.83 | 4.43 |
Minority Interest in Earnings | 0.74 | 0.74 | - | - | - | - |
Net Income | 32.01 | 42.92 | -96.83 | -12.92 | 2.83 | 4.43 |
Net Income to Common | 32.01 | 42.92 | -96.83 | -12.92 | 2.83 | 4.43 |
Net Income Growth | - | - | - | - | -36.04% | - |
Shares Outstanding (Basic) | 530 | 522 | 498 | 321 | 346 | 32 |
Shares Outstanding (Diluted) | 530 | 522 | 498 | 321 | 348 | 32 |
Shares Change | 5.53% | 4.77% | 55.49% | -7.99% | 982.64% | - |
EPS (Basic) | 0.06 | 0.08 | -0.19 | -0.04 | 0.01 | 0.14 |
EPS (Diluted) | 0.06 | 0.08 | -0.19 | -0.04 | 0.01 | 0.14 |
EPS Growth | - | - | - | - | -94.05% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -144.12 | -158.06 | -313.18 | -18.17 | 10.74 | 0.31 |
Free Cash Flow Per Share | -0.27 | -0.30 | -0.63 | -0.06 | 0.03 | 0.01 |
Dividend Per Share | 0.058 | 0.058 | - | - | 0.080 | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 50.79% | 62.06% | 69.56% | 74.02% | 76.11% | - |
Operating Margin | -26.12% | -22.36% | -13.75% | -5.83% | 0.81% | - |
Profit Margin | 5.47% | 6.75% | -15.66% | -4.46% | 2.56% | - |
Free Cash Flow Margin | -24.65% | -24.86% | -50.66% | -6.27% | 9.71% | - |
EBITDA | -141.9 | -128.15 | -71.21 | -14.23 | 1.14 | - |
EBITDA Margin | -24.27% | -20.15% | -11.52% | -4.91% | 1.03% | - |
D&A For EBITDA | 10.84 | 14 | 13.79 | 2.66 | 0.24 | - |
EBIT | -152.74 | -142.15 | -85 | -16.89 | 0.9 | -0.83 |
EBIT Margin | -26.12% | -22.36% | -13.75% | -5.83% | 0.81% | - |
Effective Tax Rate | 35.54% | 26.99% | - | - | 42.30% | - |